Rocket Pharmaceuticals, Inc.
KRESLADI
severe leukocyte adhesion deficiency-I (LAD-I)
Resolved
101days ago
FDA decision · Mar 28, 2026
What's at stake
The FDA's approval decision on KRESLADI for severe leukocyte adhesion deficiency-I (LAD-I) is due Mar 28, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“KRESLADI TM received a Prescription Drug User Fee Act (PDUFA) target action date for March 28, 2026.”